| 1 |
31212607 | Optimization of Polyarginine-Conjugated PEG Lipid Grafted Proliposome Formulation for Enhanced Cellular Association of a Protein Drug. | 2019 Jun 11 |
1 |
| 2 |
26093057 | Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer. | 2015 Oct |
1 |
| 3 |
18701868 | [Doxil--pegylated liposomal doxorubicin]. | 2008 Aug |
1 |
| 4 |
15289836 | Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review). | 2004 Sep |
1 |
| 5 |
15717735 | Advantages of liposomal delivery systems for anthracyclines. | 2004 Dec |
1 |
| 6 |
15717736 | Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. | 2004 Dec |
1 |
| 7 |
12736762 | A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. | 2003 May |
1 |
| 8 |
11750714 | Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. | 2002 Jan |
1 |
| 9 |
10811504 | Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study. | 2000 Mar |
1 |
| 10 |
11938765 | [Methodological study on the assay of glycosylphosphatidylinositol-specific phospholipase D activity in serum]. | 1999 |
1 |